2020 Annual Global Meeting: Virtual-Master Session: Cervix Cancer

Video Transcription

Video Summary

In summary, the video discussed ongoing clinical trials investigating the use of pembrolizumab, a checkpoint inhibitor, in the treatment of locally advanced cervical cancer. The trials are based on promising data showing improved response rates in metastatic disease. Other trials are exploring the role of adjuvant chemotherapy following chemoradiation to reduce distant failures. The Outback trial is studying the use of carboplatin and paclitaxel after chemoradiation in cervical cancer, and results are being analyzed. Neoadjuvant chemotherapy is also being explored, with conflicting results from different trials. The Interlace trial is currently ongoing to assess the efficacy of neoadjuvant chemotherapy. The STARS trial from China compared different treatment arms and found that sequential treatment had better outcomes for high-risk patients, but further investigation is needed for the standard chemoradiation arm. The video also discussed the importance of research in low-middle-income countries, initiatives like the Cervical Cancer Research Network, and challenges in treating cervical cancer in under-resourced areas. Alternative treatment strategies like chemotherapy and surgery, as well as proton therapy and MEK inhibitors, were briefly mentioned. The video aimed to provide information on ongoing research and efforts to improve cervical cancer care.

Keywords

pembrolizumab

checkpoint inhibitor

locally advanced cervical cancer

clinical trials

metastatic disease

adjuvant chemotherapy

chemoradiation

Outback trial

carboplatin

paclitaxel

neoadjuvant chemotherapy

Interlace trial

STARS trial

high-risk patients

low-middle-income countries